CA2172538C - Self-setting calcium phosphate cements and methods for preparing and using them - Google Patents

Self-setting calcium phosphate cements and methods for preparing and using them

Info

Publication number
CA2172538C
CA2172538C CA002172538A CA2172538A CA2172538C CA 2172538 C CA2172538 C CA 2172538C CA 002172538 A CA002172538 A CA 002172538A CA 2172538 A CA2172538 A CA 2172538A CA 2172538 C CA2172538 C CA 2172538C
Authority
CA
Canada
Prior art keywords
phosphate
calcium
cement
composition
calcium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002172538A
Other languages
French (fr)
Other versions
CA2172538A1 (en
Inventor
Laurence C. Chow
Shozo Takagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American Dental Association Health Foundation
Original Assignee
American Dental Association Health Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Dental Association Health Foundation filed Critical American Dental Association Health Foundation
Publication of CA2172538A1 publication Critical patent/CA2172538A1/en
Application granted granted Critical
Publication of CA2172538C publication Critical patent/CA2172538C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/02Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/50Preparations specially adapted for dental root treatment
    • A61K6/54Filling; Sealing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/60Preparations for dentistry comprising organic or organo-metallic additives
    • A61K6/69Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/831Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
    • A61K6/838Phosphorus compounds, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/849Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
    • A61K6/864Phosphate cements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/849Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
    • A61K6/873Carbonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00Preparations for dentistry
    • A61K6/80Preparations for artificial teeth, for filling teeth or for capping teeth
    • A61K6/849Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
    • A61K6/876Calcium oxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02Inorganic materials
    • A61L27/12Phosphorus-containing materials, e.g. apatite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005The prosthesis being constructed from a particular material
    • A61F2310/00179Ceramics or ceramic-like structures
    • A61F2310/00293Ceramics or ceramic-like structures containing a phosphorus-containing compound, e.g. apatite

Abstract

The invention includes methods and compositions relating to calcium phosphate cements, which self-harden substantially to hydroxyapatite at ambient temperature when in contact with an aqueous medium. More specifically the cements comprise a combination of one or more sparingly soluble calcium phosphate other than tetracalcium phosphate with an aqueous solution adjusted with a base to maintain a pH of about 12.5 or above and having sufficient dissolved phosphate salt to yield a solution mixture with phosphate concentration equal to or greater than about 0.2 mol/L.

Description

2~~~538 WO 95/08319 pt"1'/US94110819 SELF-SETTING CALCIUM PHOSPHATE CEMENTS
AND METHODS FOR PREPARING AND USING THEM
This invention was made in the course of research partially supported by a government grant from the National Institute of Dental Research (Grant No.
DE
05030). The U.S. government has certain rights in the invention.
Background of the Invention S 1. Field of the Invention This invention relates to calcium phosphate compositions, including cements and pastes, and to methods for making and using them. In its preferred form, the invention relates to methods for making hydroxyapatite forming cements and pastes without the necessity for employing tetracalcium phosphate as a precursor.
2. Description of Related Art In the area of dental cements, the prior art includes a number of compounds. Some such cements, however, irritate the pulp and are unsuitable for applications where the cement must come in contact with exposed pulp. Guide to Dental Materials and Devices, 7th Ed. (ADA 1974) p. 49. One solution to this problem is a cement made of materials similar in composition to tooth and bone mineral, since this would not irritate the living tissue. It has been known for some time that hydroxyapatite materials have the basic properties of human bones and teeth.
The use of p-Ca3(P04)2 was suggested for pulp capping in Driskell et al., "Development of Ceramic and Ceramic Composite Devices for Maxillofacial Application", J. Biomed. Mat. Res. 6: 345-361 ( 1972); and the use of Ca4(P04)20 was suggested by Brown and Chow in IADR Abstract No. 120, J. Dent. Res. 54: 74 (1975), as a possible pulp capping agent. As described in the latter, Ca4(P04)z0 hydrolyzes to hydroxyapatite. Such single calcium phosphate cements are incapable of setting to a hard consistency, however, without an additional source of calcium.
Though U.S. Pat. No. 3,913,229 (Driskell et al.) discloses putty-like pastes containing a-Ca3(P04)2, p-Ca3(P04)Z, CaHP04 and mixtures thereof as pulp capping, root canal, and tooth replanting materials, it is believed that none of these pastes hardens into a cement.

WO 95/08319 ~ f PCT/US94/10819 Experience with calcium-based implants for the replacement of skeletal tissue has also existed for many years. Most of these implants have been in the form of prefabricated, sintered hydroxyapatite in either granule or block forms.
These preparations have several drawbacks, including a limited ability to conform to skeletal defects, particularly in the case of blocks; inadequate structural integrity of granules (which do not bond together), and difficulty in modeling the implant to the shape of missing skeletal tissue with both blocks and granules.
The block form of hydroxyapatite provides structural support, but among other complications, must be held in place by mechanical means, which greatly limits its use and its cosmetic results; and it is very difficult to saw a shape such that it fits the patient's individual defect. The granular form produces cosmetically better results, but has a very limited structural stability and is difficult to contain during and after a surgical procedure. In general, all of these products are ceramics, produced by high temperature sintering, and are not individually crystalline, but rather have their crystal boundaries fused together. These ceramic-type materials are in general functionally biologically non-absorbable (having an absorption rate generally not exceeding on the order of 1% per year).
A porous, non-resorbable material based on coral allows intergrowth with bone, but ultimately becomes only approximately 20% bone with the remaining 80% subsisting as scar tissue. HA RESORB made by Osteogen is a form of absorbable hydroxyapatite, but is not a cement. It is granular and not adhesive.
HA RESORB is loosely rather than adhesively packed into place. For large uses, it is replaced by bone too quickly. In the dental materials market, HAPSET is a composition of calcium phosphate granules and cementable plaster of Paris (calcium sulfate). This material is not truly a hydroxyapatite and contains too much calcium sulfate for most biological uses. The calcium sulfate component of such a composition is resorbable, but not the calcium phosphate granules.
In sum, the commercially available hydroxyapatite materials are in general not resorbable with accompanying replacement by bone, and are not self-setting (self-hardening) cements.
The patent literature, does, however, describe at least one class of calcium phosphate cement compositions which are precursors for the formation of hydroxyapatite and are biologically compatible, and have two unique properties that are not attainable in other calcium phosphate biomaterials: ( I ) self-hardening to form a mass with sufficient strength for many medical and dental applications, and (2) when implanted in bone, the cement resorbs slowly and is completely St,~11O1pE SNE~eTT (RUlE 26) _ 3 _ 21 7 25 38 replaced by new bone formation with no loss in the volume or integrity of the tissue that receives the implant. See U.S.
Patents Nos. Re. 33,221 and Re. 33,161 to Brown and Chow) which teach preparation of calcium phosphate remineralization compositions and of a finely crystalline, non-ceramic, gradually resorbable hydroxyapatite cement based on the same calcium phosphate composition.
A virtually identical calcium phosphate system which consists of tetracalcium phosphate (TTCP) and monocalcium phosphate (MCP) or its monohydrate form (MCPM) was described by Constantz et al. (U. S. Patents 5,053,212 and 5,129,905).
This cement system is believed to involve conversion of the MCP to dicalcium phosphate which reacts with TTCP and forms hydroxyapatite (HA), the major mineral component of teeth and bone, as the end product.
Constantz et al. U.S. Patents 4,880,610 and 5,047,031 describe another cement system that consists of a mixture of solid phosphoric acid crystals, calcium carbonate) and calcium hydroxide as the cement powder and a 7.4 mol/L
NaOH solution (4.5 g NaOH in 15 mL of water) as the cement liquid. Data on the physical and chemical properties (compressive strength, hardening time, nature of .end product, pH of the cement fluid, heat of mixing etc.) of this cement have not been located in the patent or scientific literature.
The major components of the calcium phosphate remineralizing slurries, pastes and cements taught in U.S.
Patents Nos. Re. 33,221 and Re. 33,161 are preferably tetracalcium phosphate (Ca4(P04)20), and at least one other sparingly soluble calcium phosphate, preferably dicalcium phosphate anhydrous (CaHP04), or dicalcium phosphate dihydrate (CaHP04 ~ 2H20). These react in an acqueous environment to form hydroxyapatite, the principal mineral in teeth and bones, as the final product. Because of the apatitic nature of the set cement, it is highly compatible with soft and hard tissues. This material, if applied intraoperatively as a paste, subsequently sets to a structurally stable implant composed of microporous hydroxyapatite.
U.S. Patent No. 5,149,368, issued 22 September 1992 to Liu et al. discloses tetracalcium phosphate-containing cements having relatively high surface pH for use as a biological cement.
European Patent Application Publication No.
0416761A1 of Norian Corporation discloses calcium phosphate cements made using a phosphoric acid source substantially free of uncombined water and a calcium source.
SUI~ARY OF THE INVENTION
The materials of Brown and Chow U.S. Patents Nos.
Re. 33,221 and Re. 33,161, while highly useful) are relatively expensive because of the cost of tetracalcium phosphate.
Applicants have discovered that use of tetracalcium phosphate may be avoided in the preparation of the calcium phosphate cement composition, while still yielding a product which self-sets to hydroxyapatite, provided: (1) a high free phosphate concentration is maintained in the precursor slurry solution, and/or (2) the pH is substantially elevated above neutral. In particular) applicants have discovered that the use of a ,I

calcium phosphate precursor slurry without TTCP, which has a phosphate concentration in the solution at or above about 0.2 mol/L and/or a pH in the range of from about 12.5 to about 14 results in a cement which sets reliably and quickly to HA
without the use of tetracalcium phosphate in the precursor mixture. Applicants have also discovered that the rate of conversion to HA is unchanged for calcium phosphate cements prepared by this method and setting times are improved. The setting rate can be adjusted for various end uses) and may be quite rapid if desired. The inventive hydroxyapatite cement is believed to be both biocompatible and resorbable (biodegradable) with bone replacement when in contact with living bone.
The invention includes a method for preparing calcium phosphate cement which self-sets to hydroxyapatite as a major product at ambient temperatures comprising combining a calcium phosphate salt having a calcium to phosphorus molar ratio of less than 5 to 3 which is other than tetracalcium phosphate with an additional source of calcium and an aqueous solution adjusted with base to maintain a pH of about 12.5 or above and having a concentration of phosphate of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid. The invention further includes a method for making a calcium phosphate cement which self-sets to hydroxyapatite as a major product at ambient temperatures comprising combining a calcium phosphate salt which is other than tetracalcium phosphate, consisting essentially of dicalcium phosphate or dicalcium phosphate dihydrate, with an additional source of - 5a -calcium and an aqueous solution ad~usted with base to maintain a pH of about 12.5 or above. Alternatively) the inventive method may involve utilization of both these sets of conditions simultaneously.
The invention further includes a composition, which self-hardens to hydroxyapatite as a major product at ambient temperatures, comprising a calcium phosphate salt which has a calcium to phosphorus molar ratio of less than 5 to 3 and which is other than tetracalcium phosphate, a calcium to phosphorus molar ratio of less than 5 to 3) an additional source of calcium, and an aqueous solution adjusted with base to maintain a pH of about 12.5 or above and having a concentration of phosphate of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid.
The invention further contemplates the cement components) provided to the user in a pre-manufactured kit or delivery device, the methods of using the improved cement, and the biological implants made from the cement. A self-hardening industrial cement is also contemplated.
The techniques previously commercially available for repair of cranio- and maxillofacial defects) periodontal defects, bone fractures and other dental and orthopedic defects which could not be successfully self-healed relied heavily on the use of metallic and ceramic inserts and prostheses which might remain indefinitely as foreign objects in the body of a human or veterinary patient. As such, these prior art techniques suffered from a host of related problems) including possible refection, sites for infection, structural ...
. 61368-1066 - 5b -failure) injury to neighboring tissue and the like. Metals are difficult to shape and are hampered by problems such as infection and corrosion. Polymers such as silicone, PROPLAST, or methyl-methacrylate are encapsulated by scar tissue result ing in significant rates of implant infect ion and/or extrusion. Biologic materials, such as autogenous bone grafts) may cause donor site morbidity) may suffer from significant post-implantation resorption, and are difficult to accurately conform to skeletal defects. U.S. Patents Nos. Re.
33) 221 and Re. 33, 161 offer the alternat ive of a hydroxyapatite-forming calcium phosphate cement which is biocompatible and which when implanted in contact with living bone, is largely if not completely replaced by new bone formation, with no significant loss in the volume or integrity of the tissue that receives the implant. The above-cited patents to Brown and Chow teach the preparation of bioresorbable cements preferably from combinations of tetracalcium phosphate (Ca4(P04)20) and another sparingly soluble calcium phosphate compound, preferably dicalcium phosphate or dicalcium phosphate dihydrate. The preparation of calcium deficient HA from specially prepared and stored tetracalcium phosphate and another sparingly soluble calcium phosphate compound is also known in the art.
The inventive method described and claimed herein results in cements which are characterized by many important advantages as compared with traditional hydroxyapatite materials, and which are significantly less expensive than those of Brown and Chow and of Chow and Takagi, cited above.

- 5c -An object and advantage of the present invention is the provision of a method for preparing a self-setting calcium phosphate cement which results in particularly rapid setting of the cement.

WO 95/08319 ~ ~ 7 ~ 5 3 8 A further object and advantage of the invention is the provision of a method for making a calcium phosphate cement which employs less expensive starting materials than prior art cements of comparable properties.
Further objects and advantages of the invention include the cement mixtures prepared by the inventive method, the methods of using the cements, and the products made from them embodying the characteristics set forth above.
Additional advantageous attributes of the inventive cement include the following: The cement is easy to use and can be readily modeled to accurately reconstruct bony cavities and missing bone and to recreate contour defects of relatively non-stress bearing skeletal bone.
The cement or paste consistency enables the hydroxyapatite to conform exactly to the contours of a defect. The cement can be applied to a defect, e.g., with a spatula, can be molded and sculpted, and will hold its shape satisfactorily until set. The inventive cement sets at ambient temperature, e.g., room or body temperature, unlike the ceramic-type calcium phosphate cements which must be sintered at high temperature in a process that fuses individual hydroxyapatite crystals to each other. The cement setting reaction for the inventive material is isothermic (negligible heat is generated) and thus does not result in heat-generated necrosis of any of the neighboring tissue.
The inventive cement can be easily sculpted in vivo (intraoperatively) even after setting. When applied to clean, non-infected bone, the cement adheres to the bone, thereby greatly increasing its possible applications. Additionally, the inventive cements of the present invention are especially useful in in vitro applications, including the creation of implants. In general, the cement can be adapted to many applications.
The instant cement represents a highly biocompatible tissue substitute precursor or synthetic implant material for skeletal reconstruction. This biocompatibility stems from the fact that calcium phosphate exists in bone in the form of hydroxyapatite) and it is therefore a chemically natural material.
Basically, the inventive cement is regarded by the body as a native material;
the elevated pH which characterizes certain forms of the cement rapidly diminishes to neutral and therefore presents little threat of injury to the surrounding tissue.
SU~T11U~E SHEET (RUiE 2G~

WO 95/08319 pCT/US94/10819 BRIEF DESCRIPTION OF THE DRAWINGS
FIGURES la and lb show the solubility phase diagram of the 3-component system, Ca(OH)2-H$P04-HzO, in which both the solid phase and the saturated solution contain only those ions or non-charged species that are derived from the three components, Ca(OH)2, H~P04 and H20.
s~u~ s~~~ ~s~

217 2 ~ ~ ~ PCT/US94/10819 -g_ DESCRIPTION OF THE PREFERRED EMBODIMENTS
The complete disclosures of U.S. Patents Nos. Re. 33,221 and Re. 33,161 and pending application Serial No. 08/030,709 are expressly incorporated herein by reference.
The inventive hydroxyapatite cement is an alternative to the self-setting cement of calcium phosphate compounds developed by Brown and Chow and referenced above. The preferred major components of the calcium phosphate cement of Brown and Chow are tetracalcium phosphate (TTCP) and dicalcium phosphate anhydrous (DCPA) or dicalcium phosphate dihydrate (DCPD). These react in an aqueous environment to form hydroxyapatite (HA), the principal mineral component of teeth and bones, as the final product.
The chemical reaction that occurs during the setting of the TTCP-DCPA
(or TTCP-DCPD) cement described in Brown and Chow (Re. 33,161 and 33,221) can be represented by the following equation:
Ca4(P04)20 + CaHP04 [~ 2Hz0] -----> Ca5(P04)30H + [2H20] ( 1 ) TTCP DCPA [DCPD] HA
As described later, the choice of TTCP and DCPA (DCPD) as the cement ingredients is important because the solubilities of TTCP and DCPA are such that the cement fluid, which is approximately saturated with respect to both salts, would have a slightly above neutral pH (about 7.5 to 8.5) and sufficiently high calcium (Ca) and phosphate (P) concentrations so that the solution is substantially supersaturated with respect to HA. Rapid HA formation and concomitant dissolution of both cement ingredients, TTCP and DCPA, lead to the hardening of the cement ordinarily within 30 minutes or less.
Figures la and lb show the solubility phase diagram of the three-component system, Ca(OH)2-H3P04-H20, in which both the solid phase and the saturated solution contain only those ions or non-charged species that are derived from the three components, Ca(OH)Z, H3P04, and H20. Each curve, or solubility isotherm, in the diagram represents the composition (in terms of the pH and calcium concentration in Fig. la and the pH and phosphate concentration in Fig.
1 b) of a series of solutions that are all saturated with respect to a given salt. A
calcium phosphate salt that has a solubility isotherm that lies below that of another salt is less soluble (and more stable) than the other salt. It can be seen in the figures that among all calcium phosphate salts, HA is the least soluble in a wide range of solution pH's, ranging approximately from 4.5 to 14. Thus, ~~~'tTtit~ S~E~ ~R~J~ Z~~

__ wo 9sios319 within this pH range, any other calcium phosphate or mixture of calcium phosphates has the tendency to dissolve and reprecipitate as HA. However, in general the rate of HA formation is very slow such that a slurry of DCPD, DCPA, octacalcium phosphate (OCP), amorphous calcium phosphate (ACP), a-tricalcium phosphate (a-TCP), p-tricalcium phosphate (~i-TCP), or a mixture of these salts does not produce a setting cement or act as an effective remineralizing agent.
It has now been discovered that HA formation in calcium phosphate slurries can be greatly accelerated by one or both of the following factors:
(1) a high phosphate concentration in the slurry solution, and (2) a high degree of supersaturation with respect to HA produced by raising the solution pH to a level where most of the phosphate is in the form of P043- and little phosphate is in the form of H3P04 or HZPO,~-.
It is believed that the key to the inventive cement system is to provide effective means to accelerate the HA formation in the slurry systems that do not contain TTCP. This can be achieved by producing and maintaining a high phosphate concentration (e.g., 0.2 mol/L or higher), a high degree of supersaturation with respect to HA by raising the solution pH to about 12.5 or above, or both. It is noted that in all cases, the pH of the slurry must be in the range of approximately 4.5 to 14, the range in which HA is the most stable phase.
Once this is achieved, rapid HA formation and subsequent cementation can occur in practically any calcium phosphate slurries. Described below are approaches to attain high phosphate concentration and high degree of HA supersaturation in the slurry solutions.
In one embodiment, the invention involves producing and maintaining a high phosphate concentration in the calcium phosphate slurry solution.
Contrary to what appears to be the most obvious method to achieve the goal, adding phosphoric acid to a calcium phosphate slurry is not the method of choice to increase the phosphate concentration to 0.2 mol/L or higher. This is because as long as the slurry solution remains as a three-component system, Ca(OH)2-H3P04 HZO, the phosphate concentration is limited by the solubility isotherms of the solid that is in contact with the solution (Fig. Ib). Thus, after adding 0.2 mol/L
of phosphoric acid, the pH of the slurry would drop to significantly below 4.5 initially. As the calcium phosphate crystals dissolve and pH increases, the phosphate concentration would drop to below 0.1 mol/.' as the pH increases to 4.~
(Fig. lb). An effective way to increase the phosphate concentration is to add a non-calcium-containing salt of phosphoric acid that is sufficiently soluble, e.g., SIlBS1t~11tE SNEET (RiIL~ 26) WO 95/08319 2 i 7 ~ 5 ~ 8 PCT/US94/10819 Na3P04, Na2HP04, or NaHzP04. Salts of other cations such as K+, NH4+, etc., would work equally well provided that the cations do not form strong complexes with phosphate to the point of making phosphate unavailable for HA
precipitation.
S The reason why a high phosphate concentration can be maintained by adding an appropriate amount of sodium phosphate salt is explained as follows.
In the example where the pH is between 7.2 and 12.7, since the solution would always have a Na+ concentration of 0.4 mol/L (regardless of the calcium phosphate dissolution and precipitation reactions that may occur), the total anion concentration in the solution must be such that the anions can provide sufficient negative charges to balance the positive charges of the Na+ ions. Since OH-and phosphate ions are the only anions present in the solution, and since OH-concentration would be only 0.01 mol/L even at pH of 12, most of the negative charges have to be provided by the phosphate ions. Further, because in this pH
range the dominant phosphate species is HP04z-, the total phosphate concentration needed to balance the positive charges of the Na+ ions would be approximately 0.2 mol/L.
A second embodiment of the invention involves increasing the degree of supersaturation with respect to HA by increasing the pH to approximately 12.5 or above. The pH can be increased by adding a strong base, e.g., NaOH, KOH, etc.
Ca(OH)2 by itself is insufficient to increase the HA formation significantly, but it needs to be included as a solid component as described later. It is noted that raising the pH to 12.5 or above also increases the solubility of those calcium phosphate salts that have HPO42- ions in their structures because at pH above approximately 12.7 the dominant phosphate species is the PO43~ ion. Thus, for slurries that contain these salts, a high phosphate concentration can also be obtained by increasing the pH of the slurry solution to approximately 12 or above.
In contrast, raising the pH would not be effective in increasing the phosphate concentration in slurries that contain ACP, a-TCP, or p-TCP.
Regardless of which embodiment of the invention is used, certain considerations apply to the cement setting reactions. The formation of HA and dissolution of the more soluble calcium phosphate compounds are responsible for the hardening of the cement. Since all calcium phosphates that will be used in the cement starting ingredients have Ca/P molar ratio below 5/3, the Ca/P
ratio of HA, an additional source of calcium is needed to form HA as the dominant cement end product. For example, Ca(OH)z, Ca0 and CaC03 can be used for this suesrr~ur~ s~~r (eu~ 2s) ~~~~5~~8 WO 95/08319 pCT/US94/10819 purpose. To achieve complete conversion to HA, the cement should contain stoichiometric amounts of the calcium phosphate ingredients according to the setting reaction. Given below are some representative reactions:
3 CaHP04 + 2 Ca(OH)Z -----> Cab(PO,t)30H + 3H20 (3) 3 CaHP04 + 2 Ca0 -----> Ca5(P04)s OH + H20 (4) 3 CaHP04 + 2 CaCOg -----> Ca5(P04)sOH + H20 + 2 C02 (5) 3 a-Cas(P04)z + Ca(OH)2 -----> 2Ca5(PO,t)$OH (6) 3 CaHP04 ~ 2Hz0 + 2Ca(OH)2 ----> Cab(PO,~)sOH + 9 Hz0 (7) 3 amorphous Ca3(P04)2 + Ca(OH)Z ---- Cas(P04)$OH (8) Calcium phosphate cements were made using the methods of the present invention as follows:
A calcium phosphate cement powder was prepared by mixing a calcium phosphate salt (substantially free of tetracalcium phosphate) such as DCPA, DCPD) a-TCP or ACP with an additional source of calcium such as CaCOs, Ca(OH)2, or CaO. These calcium components may be mixed as received from vendors or ground to smaller particle size. Table I below provides examples of specifications for particles size of the components.
The calcium phosphate cement of the present invention was made by mixing 0.3 gram of calcium phosphate cement powder with 0.075 mL of an aqueous solution of a non-calcium containing salt of phosphoric acid, with powder to liquid weight ratio (P/L) of about 3, such as 1 M NaZHP04 (P/L = 3), O.SM
NaZHP09 (P/L = 3), SM (NH4)zHP04 (P/L = 2.5). 1 N NaOH and 4N NaOH
solutions were also used to formulate the cement. To allow testing of the setting time and strength of the cement, the mixture was spatulated on a glass slab for sec, and placed in a stainless steel mold (6 mm d x 3 mm h). The top and bottom surfaces of the mold were tightly covered with glass plates and the mold was placed in a 100% humidity box kept at 37° for 4 hours. The sample was removed from the mold and placed in a small amount of water for 20 hours. The 30 diametral tensile strength (DTS) was measured with the use of a Universal Testing Machine (United Calibration Corp., Garden Grove, CA) at a cross-head speed of 1 mm/min. The results of the settings times and the DTS testing are recorded in Table II.
Powder x-ray diffraction (XRD) measurements were taken of the samples to measure the conversion to HA. The samples were first ground into a fine S9~S1t1UTE SHEEN (~~'~ 26) WO 95/08319 217 2 5 3 8 pCT/US94/10819 powder form by hand grinding with the use of a mortar and pestle.
Approximately 0.25 grams of sample was placed on the sample holder. A
computer-controlled powder x-ray diffractometer (Rigaku, Danvers, MA) with CuKa radiation generated under the conditions of 40 kv and 25 mA was used to obtain the XRD patterns. Data were collected in the 2 8 scanning mode using a step width of 0.01° and count time of 2 sec.
Table I - Specification of Ingredients Median particl~
de Description size (um) DCPA Dicalcium phosphate anhydrous (JT Baker, 11.9 Inc.) (CaHPO~) DCPA (g) DCPA ground in 95% ethanol in a planetary 0.65 mill for 24h Ca(OH)2 Calcium hydroxide (Fisher Scientific Co.) 4.5 (Ca(OH)Z) Ca(OH)2 Ca(OH)2 ground in cyclohexane for 6h 1.36 (g) Ca0 Calcium oxide (CERAC/PURE, Inc.) 5.77 (Ca0) CaCOs Calcium carbonate (JT Baker) 12.4 (CaC03) CaCOg (g) CaC03 ground in cyclohexane for 16h 2.55 a-TCP a-tricalcium phosphate 12.5 (a-Ca3(P04)2) a-TCP (g) a-TCP ground in cyclohexane for 22h 2.91 ACP Amorphous calcium phosphate (Ca3(PO4)Z) DCPD Dicalcium phosphate dehydrate 7.64 (prepared in our laboratory) (CaHP04 ~ 2H20) DCPD (g) DCPD ground in 95% ethanol for 24 h 0.63 ._. WO 95/08319 21 l ~ 5 ~~ ~ p~~g94110819 Table II - Properties of Cement and Comparative Formulations Setting Conversion ExampleSolid Components Li ui P L time DTS to HA
(MPa) DCPA + Ca(OH)=

1 DCPA (g) + Ca(OH)2O.SM NaZHP04 3 7 3.9 2 DCPA (g) + Ca(OH)z1M Na2HP04 3 5 2.4 3 DCPA (g) + Ca(OH)Z1M Na2HP0~ 2.5 5 3.7t .2 - 100%
HA
4 DCPA (g) + Ca(OH)25M (NH,~)ZHP042.5 5 2.5t .2 90% +
DCP/

DCPA (g) + Ca(OH)z1 N NaOH 2.5 12 2.6t .8 - 100%
HA

6 DCPA (g) + Ca(OH)Z4N NaOH 3 10 3.9 7 DCPA (g) + Ca(OH)Z4N NaOH 2.5 5 1.5 8 DCPA + Ca(OH)2 IM Na2HP04 2.5 8 1.2t .2 HA + DCPP

9 DCPA + Ca(OH)Z 5M (NH4)ZHP043 11 .72 DCPA + Ca(OH)Z 4N NaOH 3 12 2.3 100% HA

11 DCPA (g) + Ca(OH)2(g)1M Na2HP04 2.5 10 3.9t .2 95% HA

12 DCPA (g) + Ca(OH)2(g)1 N NaOH 2.5 40 1.6t .3 95% HA

13 DCPA (g) + Ca(OH)2(g)25 mM HgP04 2.5 30 Setting Conversion ExampleSolid ComponentsLi uid ~ time DTS (MPa) to HA

DCPA + Ca0 14 DCPA + Ca0 IM Na2HP04 3 10 1.2 t 0.2 DCPA + Ca0 1 N NaOH 3 22 16 DCPA + Ca0 25 mM H3P04 3 no setting 17 DCPA (g) + Ca0 1 M NaZHP04 2.5 10 2.0 t .03 90% HA

18 DCPA (g) + Ca0 I N NaOH 2.5 10 1.7 t .5 70% HA

19 DCPA (g) t Ca0 25 mM H3P04 2.5 30 Setting Conversion Example Solid Components Li uid ~ time DTS (MPa) to HA
DCPA + CaC03 DCPA (g) + CaC03 IM Na2HP04 2.5 > 2h 1.1 10% HA
21 DCPA (g) + CaC03 5M (NH4)ZHP04 4 > 2h 1.6 ~s~~ ~~~ ~a WO 95/08319 217 2 5 3 8 p~/~594/10819 Table II - Properties of Cement and Comparative Formulations (con't.
Setting Conversion ExampleSolid Components Li uid ~ time DTS (MPa) to HA

22 DCPA (g) + CaCOs IM Na2HP0~ 3 20 1.5 t .2 99% HA
(g) 23 DCPA (g) + CaC03 1 N NaOH 3 60 1.0 t .3 90% HA
(g) 24 DCPA (g) + CaCOs 25 mM HsPO~ 3 no setting (g) Setting Conversion ExampleSolid ComponentsLi ui ~ time DTS (MPa) to HA

a-TCP and Ca0 25 a-TCP + Ca0 I M NayHPOq 2.5 2h 60%

26 a-TCP + Ca0 1 N NaOH 2.5 2h 0.8 90%

27 a-TCP + Ca0 SM (NH4)ZHP04 2.5 2h 1.7 95%

28 a-TCP + Ca0 2M Citric acid 2.5 22 1.6 29 a-TCP + Ca0 1N HCI 3 no setting 30 a-TCP (g) + 1 N NaOH 3 10 0.9 t 0.3 Ca0 31 a-TCP (g) + 25 mM H3P04 3 no setting Ca0 32 a-TCP (g) + 1M Na2HP04 3 20 0.9 t 0.4 Ca0 Setting Conversion ExampleSolid Components Li uid ~ time DTS (MPa) to HA

a-TCP + Ca(OH)s 33 a-TCP + Ca(OH)z 1M Na2HP04 2.5 no setting 34 a-TCP + Ca(OH)Z 1 N NaOH 2.5 no setting Setting Conversion ExampleSolid Components Li uid l~ time DTS (MPa) to HA

35 a-TCP + Ca(OH)2 SM (NH4)ZHP04 2.5 > 2h 6.5 36 a-TCP (g) + Ca(OH)ZIM Na2HP04 3 20 1.3 t .2 99%

37 a-TCP (g) + Ca(OH)21 N NaOH 3 no setting 38 a-TCP (g) + Ca(OH)z25 mM HsP04 3 no setting 39 a-TCP + Ca(OH)2 1M Na2HP04 3 1 day 0.2 (g) 40 a-TCP + Ca(OH)z 1 N NaOH 3 no setting (g) 41 a-TCP + Ca(OH)2 IM Na2HP04 3 20 2.7 t .2 99%

42 a-TCP(g) + Ca(OH)Z(g)1 N NaOH 3 20 1.8 t .5 99%

43 a-TCP(g) + Ca(OH)Z(g)25 mM H3P0q 3 no setting ~u~sstrrtrr~ sir (RUB 2s) WO 95/08319 217 2 5 3 8 pCT/US94/10819 Table II - Properties of Cement and Comparative Formulations (con't.l Setting Conversion ExampleSolid ComponentsLi uid ~ time DTS to HA
(MPa) a-TCP + CaCOs 44 a-TCP + CaCOs 1M NaZHP04 3 1 day 1.4 45 a-TCP + CaCOs 1N NaOH 3 no setting 46 a-TCP (g) + CaCOsIM Na2HPO,t 3 20 4.8 * 1.2 95%

47 a-TCP (g) + CaCOs1 N NaOH 3 20 2.7 * .7 95%

48 ' a-TCP (g) + CaCOs25 mM HsP04 3 no setting 49 a-TCP + CaCOs IM Na2HP04 3 1 day (g) 50 a-TCP + CaCOs 1 N NaOH 3 no setting (g) 51 a-TCP(g) + CaCOs(g)1M Na2HP04 3 20 7.5 * .5 99%

52 a-TCP(g) + CaCO~(g)1 N NaOH 3 75 2.7 * .6 99%

53 a-TCP(g) + CaC03(g)0.2M Na2HP04 3 15 3.7 * 1.3 Setting Conversion Example Solid Components Liauid ~ time DTS (MPa) to HA
ACP + Ca(OH)=
54 ACP + Ca(OH)Z 1M NazHP04 1.3 18 .14 55 ACP + Ca(OH)Z IN NaOH 1.3 25 -0 Three-Component 56 DCPA(g) + Ca(OH)2 IM NaZHP04 2.5 12 3.9 HA + CaCO
+ CaC03 DCPD + Ca(OH)=
57 DCPD{g) + Ca(OH)Z(g) 1 M Na2HP04 3 10 1.5 * 0.3 58 DCPD(g) + Ca(OH)2(g) 1N NaOH 3 21 2.0 * 0.4 Additional data points on DCPD + Ca(OH)2 cement indicate that DCPD
is very similar to DCPA in terms of the resulting cement properties. It is believed that OCP setting will generally be slower. p-TCP is considered to be the least desirable calcium phosphate salt to be used in the invention.
SU9S1t1UtE SNE~P' (R!1! E 26) WO 95/08319 ~ PCT/US94/10819 While the liquid phase that must be used with the new cements may be less biocompatible for certain clinical applications, and at present the strength of the inventive cement is lower than the best values obtainable for the TTCP-containing calcium phosphate cement, the new calcium phosphate cement is believed highly useful in most applications. The inventive hydroxyapatite cement is sufficiently structurally stable for reconstruction and augmentation of relatively non-stress-bearing bony tissue, although without augmentation, it may not have suf f icient shear-strength resistance to f unction in the reconstruction of stress-bearing bones.
The inventive cement may be supplied to the user in a variety of forms, including as powders or as a powder mixture which is later mixed with the liquid diluent to make putty; or as a pre-mixed putty which may contain a nonaqueous extender, e.g., glycerin and/or propylene glycol. It may be supplied with or in the instrumentation which is used to introduce the cement into the body, for example, a syringe, percutaneous device, "gun", cannula, biocompatible packet, dentula, reamer, file, or other forms which will be apparent to those of ordinary skill in the art. It is contemplated that the cement, in any of these forms, may be made available to the surgeon, veterinarian or dentist via a kit containing one or more of its key components. The cement is generally provided or employed in a sterilized condition. Sterilization may be accomplished, e.g., by gamma-ray radiation, typically at a dose of 2.5 Mrad.
The inventive cement may be employed in a variety of medical, dental and veterinarian procedures to substitute for missing or defective bone or tooth tissue. For example, it is contemplated that the cements of the present invention may be used in place of any of the cements known in the prior art as: ( 1 ) cavity bases and liners to protect the pulp, (ii) materials for capping exposed pulps, (iii) materials to replace or promote regeneration of bone mineral lost due to periodontal disease, (iv) direct filling materials (may be temporary) that have physical properties similar to enamel and are adhesive to enamel and dentin, (v) a cement to build up alveolar ridges in edentulous patients, (vi) an endodontic filling material for root canals, (vii) a material to cement retention pins, (viii) a material for filling sockets after a tooth extraction, (ix) a replacement of bone that has been removed surgically or lost due to trauma, (x) a cement for implanting or replanting teeth, (xi) a luting cement in dentistry and orthopedic surgery, (xii) an investment mold material, (xiii) a material which will promote bone mineral in its vicinity, (xiv) a remineralizing polish for use in place of ~"~Sdi'IUfE SHEET (RUl.~ 26) WO 95/08319 21 l ~ 5 3 8 pCT'/US94/10819 pumice, and (xv) a root cement for remineralizing and desensitizing of exposed root surfaces, (xvi) a cement for orthopedic prostheses, (xvii) a tooth implant, (xviii) a device for percutaneous passage of tubes, wires and other medical instruments through the skin, (xxix) a replacement material for bone loss due to abscess and (xxx) a self-setting cement for binding non-self-setting calcium phosphate biomaterials such as porous or non-porous HA and p-tricalcium phosphate. Reconstruction of cleft palate and other congenital skeletal defects is contemplated with use of the inventive cement, as are other forms of reconstructive and cosmetic surgery.
Various additives may be included in the inventive cements, slurries and pastes to adjust their properties and the properties of the hydroxyapatite products made from them. For example, proteins, medicaments, supporting or strengthening filler materials, crystal growth adjusters, viscosity modifiers, pore forming agents, osteoinductive factors such as demineralized bone, bone morphogenic proteins and other additives may be incorporated without departing from the scope of this invention. The referenced filler materials may include non-toxic biocompatible natural or synthetic polymers, non-toxic biocompatible metals such as titantium mesh, or other non-toxic biocompatible organic and inorganic materials. These fillers can be in the form of granules, fibers, rods, sheets or grids. These filler materials enhance the strength of the cement.
In addition, the referenced pore forming agents create pores or channels sufficiently large to cause vascularization of tissue which infiltrates the cement once placed in the body. Such pore forming agents are preferably substantially insoluble in the cement and can be removed by either resorbsion into body tissue, dissolution in physiological fluids, dissolution in solvents or heating after the cement has hardened. The pore forming agents may include sugar, sodium bicarbonate and phosphate salts. The phosphate salts are effective pore forming agents because the use of concentrated phosphate solutions in the cement makes them relatively insoluble in the cement. A particularly useful phosphate salt is disodium phosphate.
An additive of particular significance in dental applications is fluoride containing compounds. When fluoride salts such as NaF, CaFz, SnF2, NazP03F or NaZSiFs are added in sufficient quantity they increase the rate of formation of HA and fluorapatite. Preferably, the calcium phosphate cements will have a fluoride content of about 3.8%.
SUBSTITUTE SI~IEET (RULE 26) Other especially useful additives are seed crystals of HA or fluorapatite and gelling agents. Adding a sufficient quantity of crystals of HA or fluorapatite to the cement increases the rate of conversion to HA and thus reduces the setting time of the cement. Gelling agents such as hydroxypropyl methylcellulose, carboxyl methylcellulose, starch) proteoglycans and glycoproteins have the effect of causing more rapid hardening of the cement.
The novel implants thus prepared are also contemplated as part of the present invention. Where such implants contact living bone tissue, it is believed that the lack of fusion of the hydroxyapatite crystallites resulting from the setting reaction of the inventive cement will allow osteoclasts to slowly resorb the implants over time.
While the primary benefits of the present invention are believed to relate to dental, medical and veterinary applications, it is also contemplated that the techniques may be employed in conjunction with an industrial hydroxyapatite cement, for example, to repair damage, e.g., from corrosion, to marble and other stone articles.
It should be understood that the foregoing disclosure emphasizes certain specific embodiments of the invention and that all modifications or alternatives equivalent thereto are within the spirit or scope of the invention as set forth in the appended claims.

Claims (40)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A method for making a calcium phosphate cement which self-sets to hydroxyapatite as a major product at ambient temperatures comprising combining a calcium phosphate salt having a calcium to phosphorus molar ratio of less than 5 to 3 which is other than tetracalcium phosphate with an additional source of calcium and an aqueous solution adjusted with base to maintain a pH of about 12.5 or above and having a concentration of phosphate of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid.
2. The method of claim 1 wherein the calcium phosphate salt is selected from the group consisting of dicalcium phosphate anhydrous, dicalcium phosphate dihydrate, .alpha.-tricalcium phosphate, amorphous calcium phosphate, octacalcium phosphate, .beta.-tricalcium phosphate, and mixtures thereof.
3. The method of claim 1 or 2 wherein the additional source of calcium is selected from the group consisting of calcium carbonate, calcium hydroxide and calcium oxide.
4. The method of any one of claims 1, 2 and 3 wherein the base employed to adjust the pH of the solution to about 12.5 or above is sodium hydroxide.
5. A method for making a calcium phosphate cement which self-sets to hydroxyapatite as a major product at ambient temperatures comprising combining a calcium phosphate salt which is other than tetracalcium phosphate, consisting essentially of dicalcium phosphate or dicalcium phosphate dihydrate, with an additional source of calcium and an aqueous solution adjusted with base to maintain a pH of about 12.5 or above.
6. A method for making a calcium phosphate cement which self-sets to hydroxyapatite as a major product at ambient temperatures comprising combining a calcium phosphate salt having a calcium to phosphorus molar ratio of less than 5 to 3 which is other than tetracalcium phosphate with an additional source of calcium and an aqueous solution having a concentration of phosphate of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid.
7. A composition, which self-hardens to hydroxyapatite as a major product at ambient temperatures, comprising a calcium phosphate salt which has a calcium to phosphorus molar ratio of less than 5 to 3 and which is other than tetracalcium phosphate, a calcium to phosphorus molar ratio of less than 5 to 3, an additional source of calcium, and an aqueous solution adjusted with base to maintain a pH of about 12.5 or above and having a concentration of phosphate of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid.
8. The composition of claim 7 further including a fluoride containing compound such that the fluoride content of the composition is in an amount sufficient to increase the rate of formation of hydroxyapatite
9. The composition of claim 8, wherein the fluoride containing compound is selected from the group consisting of NaF, CaF2, SnF2, Na2PO3F, Na2SiF6, and mixtures thereof.
10. The composition of claim 8 or 9 wherein the fluoride content in the composition is about 3.8% by weight.
11. The composition in claim 8 further including a seed crystal compound from the group consisting of hydroxyapatite and fluorapatite in an amount sufficient to reduce the setting time of the cement.
12. A composition, which self-hardens to hydroxyapatite as a major product at ambient temperature, comprising a calcium phosphate salt which is other than tetracalcium phosphate, consisting essentially of dicalcium phosphate or dicalcium phosphate dihydrate, an additional source of calcium, and an aqueous solution adjusted with base to maintain a pH of about 12.5 or above.
13. A composition, which self-hardens to hydroxyapatite as a major product at ambient temperature, comprising a calcium phosphate salt, which is other than tetracalcium phosphate, having a calcium to phosphorus ratio of less than 5 to 3, and an aqueous solution having a concentration of phosphate of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid.
14. A dental restorative having as a calcium phosphate component a composition obtainable using the method of any one of claims 1 to 6.
15. A calcium phosphate cement which is a skeletal tissue substitute precursor comprising the composition of any one of claims 7 to 13.
16. A calcium phosphate cement which is a skeletal tissue substitute precursor comprising the composition of claim 12.
17. A calcium phosphate cement which is a skeletal tissue substitute precursor comprising the composition of claim 13.
18. A calcium phosphate bone cement which self-hardens to hydroxyapatite as a major product at ambient temperature and is substantially resorable when implanted in contact with living bone comprising the composition of claim 8.
19. A calcium phosphate bone cement which self-hardens to hydroxyapatite as a major product at ambient temperature and is substantially resorbable when implanted in contact with living bone comprising the composition of claim 12.
20. A calcium phosphate bone cement which self-hardens to hydroxyapatite as a major product at ambient temperature and is substantially resorbable when implanted in contact with living bone comprising the composition of claim 13.
21. A biological implant comprised of the cement of claim 19 inserted into contact with living tissue.
22. A biological implant comprised of the cement of claim 20 inserted into contact with living tissue.
23. A method of using the tissue substitute precursor of claim 16 as a bridging agent to bond living tissues.
24. A method of using the tissue substitute precursor of claim 17 as a bridging agent to bond living tissues.
25. A method of using the tissue substitute precursor of claim 16 to augment living tissue.
26. A method of using the tissue substitute precursor of claim 17 to augment living tissue.
27. A method of using the tissue substitute precursor of claim 16 to repair bony defects.
28. A method of using the tissue substitute precursor of claim 17 to repair bony defects.
29. A kit of calcium phosphate-containing composition precursor materials comprising (1) a calcium phosphate salt which is substantially free of tetracalcium phosphate, (2) an additional source of calcium, and (3) an aqueous solution adjusted with base to maintain a pH of about 12.5 or above.
30. A kit of calcium phosphate-containing composition precursor materials comprising (1) a calcium phosphate salt which is substantially free of tetracalcium phosphate, (2) an additional source of calcium, and (3) an aqueous solution having a phosphate concentration of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid.
31. The composition of claim 7 further comprising an additive selected from proteins, medicaments, filler materials, crystal adjustors, viscosity modifiers and pore forming agents.
32. The composition of claim 31 further including a gelling agent in an amount sufficient to cause a more rapid hardening of the cement.
33. The composition of claim 32, wherein the gelling agent is selected from the group consisting of hydroxypropyl methylcellulose, carboxyl methylcellulose, starch, proteoglycans, glycoproteins.
34. The composition of claim 31 which includes medicaments such that the medicaments are released into the surrounding living tissue over a period of time.
35. The composition of claim 31 further including a filler material in sufficient amounts to significantly increase the strength of the cement.
36. The composition of claim 35 wherein the filler material is selected from the group consisting of non-toxic biocompatible natural or synthetic polymers, fibers, and granules.
37. The composition of claim 31 further including a pore forming agent such that pores or channels of diameters sufficiently large to cause vascularization of the infiltrated tissue are formed.
38. The composition of claim 37, wherein the pore forming agent is a material that is sufficiently insoluble in the cement and can be removed by dissolution in physiological fluids, or by solvents or by heating after the hardening of the cement.
39. A self-setting calcium phosphate bone cement comprising a mixture of (1) calcium phosphate salt having a calcium to phosphorus molar ratio of less than 5 to 3 and which is other than tetracalcium phosphate, (2) an additional source of calcium, and (3) an aqueous solution adjusted with base to maintain a pH of 12.5 or above and having a concentration of phosphate of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid, whereby the cement can be used to bind non-self-setting calcium phosphate biomaterials such as porous and non-porous hydroxyapatite and .beta.-tricalcium phosphate.
40. An implant constructed in vitro for reconstruction of bone or dental tissue comprising a mixture of (1) calcium phosphate salt having a calcium to phosphorus molar ratio of less than 5 to 3 and which is other than tetracalcium phosphate, (2) an additional source of calcium, and (3) an aqueous solution adjusted with base to maintain a pH of 12.5 or above and having a concentration of phosphate of about 0.2 mol/L or above, in the absence of solid crystalline phosphoric acid, whereby the mixture self-hardens substantially to hydroxyapatite at ambient temperature and can be shaped for desired applications.
CA002172538A 1993-09-24 1994-09-23 Self-setting calcium phosphate cements and methods for preparing and using them Expired - Lifetime CA2172538C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/126,502 1993-09-24
US08/126,502 US5525148A (en) 1993-09-24 1993-09-24 Self-setting calcium phosphate cements and methods for preparing and using them
PCT/US1994/010819 WO1995008319A1 (en) 1993-09-24 1994-09-23 Self-setting calcium phosphate cements and methods for preparing and using them

Publications (2)

Publication Number Publication Date
CA2172538A1 CA2172538A1 (en) 1995-03-30
CA2172538C true CA2172538C (en) 1999-11-16

Family

ID=22425179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002172538A Expired - Lifetime CA2172538C (en) 1993-09-24 1994-09-23 Self-setting calcium phosphate cements and methods for preparing and using them

Country Status (9)

Country Link
US (4) US5525148A (en)
EP (1) EP0721320B1 (en)
JP (1) JPH10504467A (en)
AT (1) ATE210950T1 (en)
CA (1) CA2172538C (en)
DE (2) DE721320T1 (en)
ES (1) ES2099687T1 (en)
GR (1) GR970300020T1 (en)
WO (1) WO1995008319A1 (en)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002065A (en) * 1988-04-20 1999-12-14 Norian Corporation Kits for preparing calcium phosphate minerals
US5962028A (en) * 1988-04-20 1999-10-05 Norian Corporation Carbonated hydroxyapatite compositions and uses
US6005162A (en) * 1988-04-20 1999-12-21 Norian Corporation Methods of repairing bone
US5525148A (en) * 1993-09-24 1996-06-11 American Dental Association Health Foundation Self-setting calcium phosphate cements and methods for preparing and using them
US5569442A (en) * 1994-11-04 1996-10-29 Norian Corporation Reactive tricalcium phosphate compositions and uses
US7150879B1 (en) 1995-05-19 2006-12-19 Etex Corporation Neutral self-setting calcium phosphate paste
US6132463A (en) 1995-05-19 2000-10-17 Etex Corporation Cell seeding of ceramic compositions
US6541037B1 (en) 1995-05-19 2003-04-01 Etex Corporation Delivery vehicle
US6117456A (en) * 1995-05-19 2000-09-12 Etex Corporation Methods and products related to the physical conversion of reactive amorphous calcium phosphate
US6287341B1 (en) 1995-05-19 2001-09-11 Etex Corporation Orthopedic and dental ceramic implants
US6027742A (en) * 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US5676976A (en) 1995-05-19 1997-10-14 Etex Corporation Synthesis of reactive amorphous calcium phosphates
US5783217A (en) * 1995-11-07 1998-07-21 Etex Corporation Low temperature calcium phosphate apatite and a method of its manufacture
US6953594B2 (en) 1996-10-10 2005-10-11 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
EP0941079B1 (en) 1996-10-16 2007-12-19 Etex Corporation Bioceramic compositions
DE69729647T2 (en) * 1996-10-16 2005-07-07 Etex Corp., Cambridge Process for the preparation of calcium phosphate of low crystallinity and process for its use
US8728536B2 (en) * 1996-10-16 2014-05-20 Etex Corporation Chemotherapeutic composition using nanocrystalline calcium phosphate paste
US5939039A (en) 1997-01-16 1999-08-17 Orthovita, Inc. Methods for production of calcium phosphate
AU6946198A (en) 1997-04-01 1998-10-22 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microspheres
US5861445A (en) * 1997-05-08 1999-01-19 American Dental Association Health Foundation Reinforcement of dental and other composite materials
JPH11347052A (en) * 1998-03-13 1999-12-21 Yuusuke Nonomura Tooth reforming device and reforming agent
FR2776282B1 (en) 1998-03-20 2000-05-19 Toulouse Inst Nat Polytech PROCESS FOR THE PREPARATION OF A HYDROXYAPATITE-BASED BIOMATERIAL, BIOMATERIAL OBTAINED AND SURGICAL OR DENTAL APPLICATION
DE19816858A1 (en) * 1998-04-16 1999-10-21 Merck Patent Gmbh Tricalcium phosphate-containing bio-cement pastes with cohesion promoters
US5858333A (en) * 1998-08-07 1999-01-12 Enamelon, Inc. Two-part oral products and methods of using same to remineralize teeth
US6383519B1 (en) * 1999-01-26 2002-05-07 Vita Special Purpose Corporation Inorganic shaped bodies and methods for their production and use
WO2000045870A1 (en) * 1999-02-04 2000-08-10 Sdgi Holdings, Inc. Osteogenic paste compositions and uses thereof
WO2000071178A1 (en) * 1999-05-19 2000-11-30 Ecole Polytechnique Federale De Lausanne (Epfl) Calcium phosphate bone substitute
EP1060731A1 (en) * 1999-06-18 2000-12-20 Bone & Joint Research S.A. Bio-active filler material, method for the use of such composition and device for the implementation of said process
DE60041971D1 (en) 1999-07-08 2009-05-20 Cap Biotechnology Inc CALCIUM-CONTAINING STRUCTURES AND METHOD FOR THE PRODUCTION AND USE THEREOF
US6840995B2 (en) * 1999-07-14 2005-01-11 Calcitec, Inc. Process for producing fast-setting, bioresorbable calcium phosphate cements
US6960249B2 (en) * 1999-07-14 2005-11-01 Calcitec, Inc. Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface
US6379453B1 (en) 1999-07-14 2002-04-30 Jiin-Huey Chern Process for producing fast-setting, bioresorbable calcium phosphate cements
US7270705B2 (en) * 1999-07-14 2007-09-18 Jiin-Huey Chern Lin Method of increasing working time of tetracalcium phosphate cement paste
US7169373B2 (en) * 1999-07-14 2007-01-30 Calcitec, Inc. Tetracalcium phosphate (TTCP) having calcium phosphate whisker on surface and process for preparing the same
US7094282B2 (en) * 2000-07-13 2006-08-22 Calcitec, Inc. Calcium phosphate cement, use and preparation thereof
US6458423B1 (en) 1999-08-03 2002-10-01 David M. Goodson Sprayable phosphate cementitious coatings and a method and apparatus for the production thereof
US6458162B1 (en) 1999-08-13 2002-10-01 Vita Special Purpose Corporation Composite shaped bodies and methods for their production and use
DE60012557T2 (en) * 1999-10-15 2005-08-04 Genetics Institute, LLC, Cambridge HYALURONIC ACID COMPOSITIONS FOR THE DISPOSAL OF OSTEOGENIC PROTEINS
US7820191B2 (en) 2000-04-28 2010-10-26 Skeletal Kinetics, Llc Calcium phosphate cements prepared from silicate solutions
US6375935B1 (en) 2000-04-28 2002-04-23 Brent R. Constantz Calcium phosphate cements prepared from silicate solutions
US7204876B2 (en) * 2000-07-13 2007-04-17 Calcitec, Inc. Calcium phosphate cements made from (TTCP) with surface whiskers and process for preparing same
US7156915B2 (en) * 2000-07-13 2007-01-02 Calcitec, Inc. Tetracalcium phosphate (TTCP) with surface whiskers and method of making same
US6599516B1 (en) 2000-09-14 2003-07-29 Etex Corporation Malleable implant containing solid element that resorbs or fractures to provide access channels
JP2004511320A (en) * 2000-10-16 2004-04-15 ユニバーシテイ・オブ・サウス・カロライナ Biocompatible cement containing reactive calcium phosphate nanoparticles and methods of making and using said cement
US6736799B1 (en) 2000-10-24 2004-05-18 Vita Licensing, Inc. Delivery device for biological composites and method of preparation thereof
US7052517B2 (en) * 2000-10-24 2006-05-30 Vita Special Purpose Corporation Delivery device for biological composites and method of preparation thereof
US6547866B1 (en) 2000-10-30 2003-04-15 Howmedica Osteonics Corp. Porous calcium phosphate cement
US6793725B2 (en) * 2001-01-24 2004-09-21 Ada Foundation Premixed calcium phosphate cement pastes
US7294187B2 (en) * 2001-01-24 2007-11-13 Ada Foundation Rapid-hardening calcium phosphate cement compositions
US7709029B2 (en) * 2001-01-24 2010-05-04 Ada Foundation Calcium-containing restoration materials
US6730324B2 (en) 2001-04-20 2004-05-04 The University Of British Columbia Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation
US6558779B1 (en) * 2001-07-03 2003-05-06 Agfa-Gevaert Ink jet recording element
US6616742B2 (en) 2001-08-30 2003-09-09 Cana Lab Corporation Process for preparing a paste from calcium phosphate cement
WO2003055418A1 (en) * 2001-12-21 2003-07-10 Lagow Richard J Calcium phosphate bone replacement materials and methods of use thereof
US6955716B2 (en) 2002-03-01 2005-10-18 American Dental Association Foundation Self-hardening calcium phosphate materials with high resistance to fracture, controlled strength histories and tailored macropore formation rates
US20040127563A1 (en) * 2002-03-22 2004-07-01 Deslauriers Richard J. Methods of performing medical procedures which promote bone growth, compositions which promote bone growth, and methods of making such compositions
WO2003093196A1 (en) * 2002-05-06 2003-11-13 Biomet Deutschland Gmbh Method of preparing porous calcium phosphate granules
US20030216777A1 (en) * 2002-05-16 2003-11-20 Yin-Chun Tien Method of enhancing healing of interfacial gap between bone and tendon or ligament
DE10228080B4 (en) * 2002-06-18 2004-07-08 Innovent E.V. Self-curing mixture and its use
JP4273073B2 (en) * 2002-06-19 2009-06-03 ドクトル.ハー.ツェー.ロベルト マシーズ スティフツング Hydraulic calcium-based hydraulic cement for surgery
BR0311971A (en) * 2002-06-20 2005-03-22 Doxa Ab System for the production of a dental filler or implant material, and powder material, hydration liquid, implant material and method of obtaining a bond
DE60300666T2 (en) * 2002-07-11 2006-04-27 Biomet Deutschland Gmbh Process for the preparation of porous calcium phosphate chips and granules from gelatine processing
AU2003262660B2 (en) * 2002-08-12 2009-07-16 Warsaw Orthopedic, Inc. Synthesis of a bone-polymer composite material
EP1394132B8 (en) 2002-08-27 2014-07-09 Tas, Ahmet Cuneyt A new calcium phosphate cement composition and a method for the preparation thereof
US20050251267A1 (en) * 2004-05-04 2005-11-10 John Winterbottom Cell permeable structural implant
US7985414B2 (en) * 2003-02-04 2011-07-26 Warsaw Orthopedic, Inc. Polyurethanes for osteoimplants
ES2541909T3 (en) 2003-02-04 2015-07-28 Warsaw Orthopedic, Inc. Osteoimplant polyurethanes
EP1622843B1 (en) * 2003-04-08 2015-06-03 Ada Foundation Premixed self-hardening bone graft pastes
KR101161784B1 (en) * 2003-04-11 2012-07-05 에텍스 코포레이션 Osteoinductive Bone Material
EP1624904B1 (en) * 2003-05-22 2007-01-03 Artoss GmbH Inorganic resorbable bone substitute material
US20040250730A1 (en) * 2003-06-12 2004-12-16 David Delaney Calcium phosphate cements prepared from silicate-phosphate solutions
US20040250729A1 (en) * 2003-06-16 2004-12-16 Jang Bor Z. Fast-setting carbonated hydroxyapatite compositions and uses
US20040254668A1 (en) * 2003-06-16 2004-12-16 Jang Bor Z. Macro-porous hydroxyapatite scaffold compositions and freeform fabrication method thereof
US7306786B2 (en) * 2003-07-28 2007-12-11 Skeletal Kinetics, Llc Calcium phosphate cements comprising a water-soluble contrast agent
US7163651B2 (en) * 2004-02-19 2007-01-16 Calcitec, Inc. Method for making a porous calcium phosphate article
US6994726B2 (en) * 2004-05-25 2006-02-07 Calcitec, Inc. Dual function prosthetic bone implant and method for preparing the same
US7118705B2 (en) * 2003-08-05 2006-10-10 Calcitec, Inc. Method for making a molded calcium phosphate article
US7261717B2 (en) 2003-09-11 2007-08-28 Skeletal Kinetics Llc Methods and devices for delivering orthopedic cements to a target bone site
US7261718B2 (en) * 2003-09-11 2007-08-28 Skeletal Kinetics Llc Use of vibration with polymeric bone cements
US20050101964A1 (en) * 2003-11-07 2005-05-12 Calcitec, Inc. Spinal fusion procedure using an injectable bone substitute
US7252833B2 (en) * 2003-11-18 2007-08-07 Skeletal Kinetics, Llc Calcium phosphate cements comprising an osteoclastogenic agent
EP1701672A4 (en) * 2003-12-19 2011-04-27 Osteotech Inc Tissue-derived mesh for orthopedic regeneration
US8012210B2 (en) * 2004-01-16 2011-09-06 Warsaw Orthopedic, Inc. Implant frames for use with settable materials and related methods of use
US20060015184A1 (en) * 2004-01-30 2006-01-19 John Winterbottom Stacking implants for spinal fusion
US7189263B2 (en) * 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US7351280B2 (en) * 2004-02-10 2008-04-01 New York University Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment
CA2552906C (en) * 2004-03-08 2014-05-13 Dr. H. C. Robert Mathys Stiftung Hydraulic cement based on calcium phosphate for surgical use
US9707024B2 (en) 2004-03-09 2017-07-18 Skeletal Kinetics, Llc Use of vibration in composite fixation
US8118812B2 (en) 2004-03-09 2012-02-21 Skeletal Kinetics, Llc Use of vibration in composite fixation
CA2562675A1 (en) * 2004-04-15 2005-12-15 Etex Corporation Delayed-setting calcium phosphate pastes
FR2869544B1 (en) * 2004-05-03 2006-07-21 Centre Nat Rech Scient Cnrse COMPOSITION FOR INJECTION CEMENT, USEFUL AS BONE SUBSTITUTE
US20050257714A1 (en) * 2004-05-20 2005-11-24 Constantz Brent R Orthopedic cements comprising a barium apatite contrast agent
US7252841B2 (en) * 2004-05-20 2007-08-07 Skeletal Kinetics, Llc Rapid setting calcium phosphate cements
US9220595B2 (en) 2004-06-23 2015-12-29 Orthovita, Inc. Shapeable bone graft substitute and instruments for delivery thereof
US7175858B2 (en) * 2004-07-26 2007-02-13 Skeletal Kinetics Llc Calcium phosphate cements and methods for using the same
ES2246726B2 (en) 2004-08-12 2007-11-01 Universitat Politecnica De Catalunya SELF-FRAGABLE AND INJECTABLE CALCIUM PHOSPHATE FOAM
US7250550B2 (en) 2004-10-22 2007-07-31 Wright Medical Technology, Inc. Synthetic bone substitute material
US20060110422A1 (en) * 2004-11-19 2006-05-25 Tas Ahmet C Conversion of calcite powders into macro- and microporous calcium phosphate scaffolds for medical applications
US20060115437A1 (en) * 2004-11-26 2006-06-01 Robert Hayman Dental whitening compositions
US20080050408A1 (en) * 2004-11-26 2008-02-28 Discus Dental, Llc Dental Whitening Compositions
US7312989B2 (en) * 2004-12-06 2007-12-25 Chenbro Micom Co., Ltd. Cooler
US7713542B2 (en) 2005-01-14 2010-05-11 Ada Foundation Three dimensional cell protector/pore architecture formation for bone and tissue constructs
US7459018B2 (en) 2005-04-08 2008-12-02 Howmedica Leibinger Inc. Injectable calcium phosphate cement
US7416602B2 (en) * 2005-04-08 2008-08-26 Howmedica Leibinger, Inc. Calcium phosphate cement
US20060233849A1 (en) * 2005-04-13 2006-10-19 Simon Bruce J Composite bone graft material
US7621963B2 (en) * 2005-04-13 2009-11-24 Ebi, Llc Composite bone graft material
EP1716873A1 (en) * 2005-04-25 2006-11-02 Progentix B.V. i.o. Method of improving the osteoinductivity of bioactive materials
US9259439B2 (en) * 2005-10-21 2016-02-16 Ada Foundation Dual-phase cement precursor systems for bone repair
US9101436B2 (en) * 2005-10-21 2015-08-11 Ada Foundation Dental and endodontic filling materials and methods
US8147860B2 (en) 2005-12-06 2012-04-03 Etex Corporation Porous calcium phosphate bone material
GB2433257A (en) * 2005-12-19 2007-06-20 Accentus Plc Preparation of hydroxyapatite
AU2007207495A1 (en) * 2006-01-19 2007-07-26 Warsaw Orthopedic, Inc. Porous osteoimplant
AU2007207429A1 (en) 2006-01-19 2007-07-26 Warsaw Orthopedic, Inc. Injectable and moldable bone substitute materials
AU2007212138B2 (en) * 2006-02-03 2010-12-16 Wm. Wrigley Jr. Company Calcium phosphate salts in oral compositions suitable as a tooth remineralizing agent
CA2656050C (en) 2006-06-29 2015-02-03 Orthovita, Inc. Kit for bone graft comprising collagen,calcium phosphate,and bioactive glass
EP1891984A1 (en) * 2006-08-24 2008-02-27 Graftys Macroporous and highly resorbable apatitic calcium-phosphate cement
US8388626B2 (en) * 2006-11-08 2013-03-05 Warsaw Orthopedic, Inc. Methods of employing calcium phosphate cement compositions and osteoinductive proteins to effect vertebrae interbody fusion absent an interbody device
US8268010B2 (en) 2007-01-12 2012-09-18 Warsaw Orthopedic, Inc. System and method for forming bone filling materials with microparticles
US8840618B2 (en) 2007-01-12 2014-09-23 Warsaw Orthopedic, Inc. System and method for pressure mixing bone filling material
US8926623B2 (en) * 2007-01-12 2015-01-06 Warsaw Orthopedic, Inc. System and method for forming porous bone filling material
ITRM20070363A1 (en) 2007-06-27 2008-12-28 Univ Bologna Alma Mater POROUS SECTOR FROM CEMENTITIOUS MATERIAL OF CALCIUM PHOSPHATE AND ITS USE IN FLUID-SCALE EQUIPMENT
CA2711847C (en) * 2008-01-09 2018-05-08 Innovative Health Technologies, Llc Implant pellets and methods for performing bone augmentation and preservation
US20100082072A1 (en) * 2008-03-28 2010-04-01 Sybert Daryl R Bone anchors for orthopedic applications
WO2009152330A1 (en) * 2008-06-12 2009-12-17 Latitude 18, Inc Inorganic phosphate resins and method for their manufacture
WO2012134540A2 (en) 2010-10-22 2012-10-04 Vanderbilt University Injectable synthetic pur composite
US9333276B2 (en) * 2008-10-30 2016-05-10 Vanderbilt University Bone/polyurethane composites and methods thereof
DK2365994T3 (en) * 2008-11-12 2017-03-27 Howmedica Osteonics Corp TETRA-CALCIUM PHOSPHATE-BASED ORGANOPHOSPHORUS COMPOSITIONS AND PROCEDURES
US8409538B2 (en) 2008-12-04 2013-04-02 Skeletal Kinetics Llc Tricalcium phosphate coarse particle compositions and methods for making the same
US8673364B2 (en) * 2009-09-28 2014-03-18 Skeletal Kinetics, Llc Rapid setting high strength calcium phosphate cements comprising cyclodextrins
EP2421543B1 (en) * 2009-04-22 2019-06-12 American Dental Association Foundation Dual-phase calcium phosphate cement composition
JP5669859B2 (en) * 2009-12-11 2015-02-18 ラティテュード・18,インコーポレイテッド Inorganic phosphate anti-corrosion coating
ES2821489T3 (en) 2009-12-11 2021-04-26 Latitude 18 Inc Inorganic Phosphate Compositions and Methods
JP5095034B2 (en) 2009-12-18 2012-12-12 ハウメディカ・オステオニクス・コーポレイション System and calcium phosphate composition for producing post-irradiation storage-stable direct-injectable dual-paste bone cement
US20130139930A1 (en) 2009-12-18 2013-06-06 Latitude 18, Inc. Inorganic phosphate corrosion resistant coatings
US20110151027A1 (en) * 2009-12-21 2011-06-23 Theodore D Clineff Strontium-doped calcium phosphate bone graft materials
KR101869568B1 (en) * 2009-12-30 2018-06-20 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Filtering face-piece respirator having an auxetic mesh in the mask body
WO2011100288A2 (en) 2010-02-09 2011-08-18 Latitude 18, Inc. Phosphate bonded composites and methods
CN101804206A (en) * 2010-04-01 2010-08-18 同济大学 Porous calcium phosphate microsphere with medicinal controlled release function, preparation method and application thereof
AU2011250934B2 (en) 2010-05-11 2016-02-25 Howmedica Osteonics Corp., Organophosphorous, multivalent metal compounds, & polymer adhesive interpenetrating network compositions & methods
WO2012003438A1 (en) * 2010-07-02 2012-01-05 Ada Foundation Fluorapatite-forming calcium phosphate cements
JP5665465B2 (en) * 2010-09-30 2015-02-04 クラレノリタケデンタル株式会社 Ivory tubule sealant
WO2012045013A2 (en) * 2010-10-01 2012-04-05 Skeletal Kinetics, Llc Porogen containing calcium phosphate cement compositions
WO2012046667A1 (en) 2010-10-06 2012-04-12 クラレメディカル株式会社 Dental canaliculi sealing agent and method for producing the same
EP2637983B1 (en) 2010-11-10 2018-12-26 Stryker European Holdings I, LLC Process for the preparation of a polymeric bone foam
US20130236517A1 (en) * 2010-11-16 2013-09-12 Doxa Ab Apatite Forming Biomaterial
US8551525B2 (en) 2010-12-23 2013-10-08 Biostructures, Llc Bone graft materials and methods
US8739332B2 (en) 2011-02-08 2014-06-03 Hill-Rom Services, Inc. Footboard with linen holder and transport shelf
US20120210909A1 (en) * 2011-02-21 2012-08-23 Tien-Min Gabriel Chu Calcim phosphate cement reinforcement by polymer infiltration and in situ curing
EP2688514A1 (en) 2011-03-21 2014-01-29 Endo Pharmaceuticals Inc. Urethral anastomosis device and method
WO2012158527A2 (en) 2011-05-13 2012-11-22 Howmedica Osteonics Organophosphorous & multivalent metal compound compositions & methods
US9163173B2 (en) 2011-12-15 2015-10-20 Halliburton Energy Services, Inc. Wellbore servicing compositions and methods of making and using same
CA2885352A1 (en) 2012-09-18 2014-03-27 Endo Pharmaceuticals Inc. Urethral anastomosis device and method
AU2014241104B2 (en) 2013-03-14 2016-07-14 Goldberg, Roger P. Urethral anastomosis device
US9827268B2 (en) 2013-08-06 2017-11-28 Kuraray Noritake Dental Inc. Curable calcium phosphate composition for biological hard tissue repair, bone repair material, and various dental materials
US9820791B2 (en) 2014-08-22 2017-11-21 Kyphon SÀRL Methods of filling bone using bone cement mixing and delivery devices
US9820792B2 (en) 2014-08-22 2017-11-21 Kyphon SÀRL Bone cement mixing and delivery device
WO2016067622A1 (en) * 2014-10-30 2016-05-06 クラレノリタケデンタル株式会社 All-in-one dentinal tubule occlusion material
US11020160B2 (en) * 2016-03-21 2021-06-01 Warsaw Orthopedic, Inc. Surgical injection system and method
US10709733B2 (en) 2016-08-11 2020-07-14 Regents Of The University Of Minnesota Nonsurgical techniques for restoring tooth enamel
US11549033B2 (en) * 2017-08-22 2023-01-10 National Institute For Materials Science Coating agent, process of forming coating films, primer treatment process, process of repairing concretes, and process of constructing roads
US11752072B2 (en) 2019-03-11 2023-09-12 University Of Utah Research Foundation Quick set cements for dental pulp capping and related methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US33221A (en) * 1861-09-03 Improvement in soap
US33161A (en) * 1861-08-27 Improvement in molds for earthen or cement pipes
US3679360A (en) * 1970-06-26 1972-07-25 Nasa Process for the preparation of brushite crystals
US3787900A (en) * 1971-06-09 1974-01-29 Univ Iowa State Res Found Artificial bone or tooth prosthesis material
US3929971A (en) * 1973-03-30 1975-12-30 Research Corp Porous biomaterials and method of making same
US3913229A (en) * 1974-02-25 1975-10-21 Miter Inc Dental treatments
US4097935A (en) * 1976-07-21 1978-07-04 Sterling Drug Inc. Hydroxylapatite ceramic
DE2928007A1 (en) * 1979-07-11 1981-01-15 Riess Guido Dr BONE IMPLANT BODY FOR PROSTHESES AND BONE CONNECTORS AND METHOD FOR THE PRODUCTION THEREOF
JPS5654841A (en) * 1979-10-08 1981-05-15 Mitsubishi Mining & Cement Co Bone broken portion and filler for void portion and method of treating bone of animal using said filler
USRE33161E (en) * 1982-04-29 1990-02-06 American Dental Association Health Foundation Combinations of sparingly soluble calcium phosphates in slurries and pastes as mineralizers and cements
USRE33221E (en) * 1982-04-29 1990-05-22 American Dental Association Health Foundation Dental restorative cement pastes
US4880610A (en) * 1988-04-20 1989-11-14 Norian Corporation In situ calcium phosphate minerals--method and composition
US5053212A (en) * 1988-04-20 1991-10-01 Norian Corporation Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite
US5047031A (en) * 1988-04-20 1991-09-10 Norian Corporation In situ calcium phosphate minerals method
US5129905A (en) * 1988-04-20 1992-07-14 Norian Corporation Methods for in situ prepared calcium phosphate minerals
US5034059A (en) * 1989-02-17 1991-07-23 Norian Corporation Composition comprising octacalcium phosphate crystals and polypeptide
DE3935060C2 (en) * 1989-10-20 1996-05-30 Herbst Bremer Goldschlaegerei Process for the production of a ceramic material for the dental field and its use
US5231169A (en) * 1990-10-17 1993-07-27 Norian Corporation Mineralized collagen
US5149368A (en) * 1991-01-10 1992-09-22 Liu Sung Tsuen Resorbable bioactive calcium phosphate cement
ES2040626B1 (en) * 1991-11-22 1994-05-16 Boltong Maria G PROCEDURE FOR THE OBTAINING OF CALCIUM PHOSPHATE CEMENTS AND THEIR USE AS BIOMTERIALS.
CA2167721A1 (en) * 1993-07-22 1995-02-02 Mark Fulmer Storage stable partially neutralized acid compositions and uses
US5525148A (en) * 1993-09-24 1996-06-11 American Dental Association Health Foundation Self-setting calcium phosphate cements and methods for preparing and using them
US5496399A (en) * 1994-08-23 1996-03-05 Norian Corporation Storage stable calcium phosphate cements

Also Published As

Publication number Publication date
JPH10504467A (en) 1998-05-06
US5997624A (en) 1999-12-07
EP0721320A1 (en) 1996-07-17
ES2099687T1 (en) 1997-06-01
DE721320T1 (en) 1997-04-10
DE69429526T2 (en) 2002-08-08
GR970300020T1 (en) 1997-07-30
ATE210950T1 (en) 2002-01-15
CA2172538A1 (en) 1995-03-30
EP0721320B1 (en) 2001-12-19
DE69429526D1 (en) 2002-01-31
US5525148A (en) 1996-06-11
US5954867A (en) 1999-09-21
US5976234A (en) 1999-11-02
WO1995008319A1 (en) 1995-03-30

Similar Documents

Publication Publication Date Title
CA2172538C (en) Self-setting calcium phosphate cements and methods for preparing and using them
CA2157890C (en) Calcium phosphate hydroxyapatite precursor and methods for making and using the same
Chow Calcium phosphate cements: chemistry, properties, and applications
US7294187B2 (en) Rapid-hardening calcium phosphate cement compositions
US5503164A (en) Device and method for repair of craniomaxillofacial bone defects including burr holes
JP3110762B2 (en) Absorbable bioactive phosphate-containing cement
US6379453B1 (en) Process for producing fast-setting, bioresorbable calcium phosphate cements
CA1332495C (en) In situ calcium phosphate minerals -- method and composition
JP3658172B2 (en) A storage stable formulation for calcium phosphate minerals prepared in situ
Chow et al. Calcium phosphate cements
US7083672B2 (en) Method and product for phosphosilicate slurry for use in dentistry and related bone cements
Chow Calcium phosphate materials: reactor response
US20040250729A1 (en) Fast-setting carbonated hydroxyapatite compositions and uses
Kazuz et al. α-Tricalcium phosphate/fluorapatite-based cement–Promising dental root canal filling material

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20140923